NEWSROOM

Healthcare

REMSleep Holdings Inc. Announces Strategic Marketing Plan for DELTAWAVE Nasal Pillows System

REMSleep Holdings Inc. Announces Strategic Marketing Plan for DELTAWAVE Nasal Pillows System

Clearwater, FL, July 17, 2024– REMSleep Holdings Inc. (OTCQB: RMSL), a pioneer in sleep apnea treatment solutions, is thrilled to announce a comprehensive marketing strategy for its revolutionary DELTAWAVE Nasal Pillows System. This strategic plan aims to significantly expand the market presence of DELTAWAVE by identifying and partnering with key distributors nationwide The DELTAWAVE Nasal Pillows System, designed with cutting-edge technology, offers an innovative solution for those suffering...

read more
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix’s HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix’s HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

NEW YORK, N.Y., July 15, 2024 – PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's (Nasdaq: SNGX) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte™ (synthetic hypericin) is a novel photodynamic therapy for the treatment of early-stage cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin’s lymphoma with no FDA-approved first-line treatments. Highlights from the Q&A:...

read more
MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in “Take Advantage of the Moment” Episode

MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in “Take Advantage of the Moment” Episode

HOLLAND, Mich., July 11, 2024 – MedTech Gurus, a leading podcast focused on the forefront of medical technology, featured Oncocyte Corporation (NASDAQ: OCX) CEO Josh Riggs in its latest episode, "Take Advantage of the Moment." In this episode, Riggs highlights Oncocyte's innovative strategies in molecular diagnostic technology and the significant impact of this technology on patient care. Hosted by Tom Hickey, a partner at Excelerant Consulting and a seasoned expert in medical device...

read more
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers

BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers

POMPANO BEACH, FL, July 10, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that the IRB has approved a clinical study to evaluate AmnioWrap2™ (AW2) in diabetic foot ulcers (DFU), one of the company’s placental-derived allograft commercial products. Jason Matuszewski, CEO of BioStem, commented: “Diabetic foot ulcers are a...

read more
American Shared Hospital Services Announces Signing of Joint Venture Agreement for Gamma Knife Facility in Guadalajara, Mexico

American Shared Hospital Services Announces Signing of Joint Venture Agreement for Gamma Knife Facility in Guadalajara, Mexico

JV will Establish Company’s 4th International Center SAN FRANCISCO, CA, July 9, 2024 ‒ American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that it has signed a joint venture agreement to partner in a Gamma Knife treatment facility in Guadalajara, Mexico. AMS has signed a Joint Venture (“JV”) agreement with Hospital San...

read more
REMSleep Holdings Inc. Receives 510(K) Clearance on Product

REMSleep Holdings Inc. Receives 510(K) Clearance on Product

CLEARWATER, FL, July 9, 2024 - REMSleep Holdings, Inc. (OTCQB: RMSL) announces the company has been awarded 510(K) Clearance for the new Deltawave CPAP Pillows Interface mask. The company would like to share the following correspondence with its shareholders: Re: K233415Trade/Device Name: DELTAWAVE Nasal Pillows SystemRegulation Number: 21 CFR 868.5905Regulation Name: Noncontinuous Ventilator (IPPB)Regulatory Class: Class IIProduct Code: BZDDated: October 4, 2023Received: October 10, 2023 Dear...

read more
ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene

ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene

Collaboration focuses on research and development of ANEW’s patented Klotho gene therapy in enhancing longevity and reducing age-related diseases ANEW’s mission is to deliver transformative protein, cell, and gene therapies in areas of high unmet medical needs, particularly targeting highly prevalent neurodegenerative diseases and age-related disorders NEW YORK, June, 27. 2024 -- ANEW MEDICAL, INC. (Nasdaq: WENA), a biopharmaceutical company specializing in the advancement of novel...

read more
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

Study published in peer-reviewed journal finds BioStem’s products offer overall better treatment efficiency, and greater efficiency in general wound closure POMPANO BEACH, Fla., June 26, 2024 -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that an article validating its proprietary processing method and its placental allograft...

read more
ANEW MEDICAL, INC. Secures Key Patent in Europe for HUMAN Klotho Gene RNA Slice Variant and Protein

ANEW MEDICAL, INC. Secures Key Patent in Europe for HUMAN Klotho Gene RNA Slice Variant and Protein

ANEW to explore therapeutics and specialty diagnostics utilizing the s-KL protein and will pursue other medical product development and commercial opportunities of interest Exclusive, worldwide intellectual property licensed from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Barcelona, Spain NEW YORK, June 26, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA) (“ANEW” or “the Company”) a biopharmaceutical company specializing in the advancement...

read more
Oncocyte Appoints Andrea James as Chief Financial Officer

Oncocyte Appoints Andrea James as Chief Financial Officer

IRVINE, Calif., June 17, 2024 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer. “We are thrilled to welcome Andrea as we approach the inflection point of commercial launch,” Oncocyte CEO Josh Riggs said. “She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and building...

read more
SS Innovations Designated “Outstanding Company” Finalist for Surgical Robotics Industry Awards 2024

SS Innovations Designated “Outstanding Company” Finalist for Surgical Robotics Industry Awards 2024

Annual awards celebrate the best of the surgical robotics industry Fort Lauderdale, FL., June 17, 2024 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, was recently selected as a finalist in the Surgical Robotics Industry Awards 2024 in the “Outstanding Company” category. The Company’s SSi Mantra Surgical...

read more
SS Innovations Designated “Outstanding Company” Finalist for Surgical Robotics Industry Awards 2024

SS Innovations’ SSi Mantra Surgical Robotic System Approved for Use in Indonesia

Fort Lauderdale, FL., June 11, 2024 - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, today announced that its SSi Mantra Surgical Robotic System has received regulatory approval from the Indonesian Ministry of Health for clinical use in the Republic of Indonesia.  With more than 279 million people,...

read more
GK Financing LLC, a Subsidiary of American Shared Hospital Services, Announces Extension of Agreement with PeaceHealth Sacred Heart Medical Center at RiverBend

GK Financing LLC, a Subsidiary of American Shared Hospital Services, Announces Extension of Agreement with PeaceHealth Sacred Heart Medical Center at RiverBend

Extended 10-year Agreement to Upgrade Gamma Knife® Perfexion™ with Elekta Esprit San Francisco, CA, June 7, 2024 – GK Financing LLC (GKF), a subsidiary of American Shared Hospital Services (NYSE American: AMS), a leading provider of turnkey technology solutions for advanced radiosurgery and radiation oncology services, announced today that it has extended its current agreement with PeaceHealth Sacred Heart Medical Center at RiverBend in Springfield, Ore. The new agreement will see the center...

read more
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

BioStem Technologies to Sponsor MRO Better Half Dash

POMPANO BEACH, Fla., May 29, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics, will sponsor the MRO Better Half Dash which will be held on May 29, 2024, from 4:00 PM – 9:00 PM at the Trackhouse Motorplex, 130 Motorplex Dr, Mooresville, NC. The Better Half Dash has become a beloved annual event in NASCAR, eagerly anticipated by fans and participants alike. Billy...

read more
SS Innovations’ SSi Mantra Surgical Robotic System Used to Perform 100 Cardiac Surgeries, Signaling Market Expansion

SS Innovations’ SSi Mantra Surgical Robotic System Used to Perform 100 Cardiac Surgeries, Signaling Market Expansion

The SSi Mantra has surpassed the 100 surgery milestone for robotic cardiac surgery SS Innovations maintains the world's only comprehensive robotic cardiac surgery program SSi Mantra used in more than 1000 procedures globally Company anticipates FDA approval in early 2025 FORT LAUDERDALE, FL, May 21, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery...

read more
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

Share:   Company to initiate Phase 2b clinical trial in lead asset, LP-10 in 2H 2024 Pittsburgh, PA, May 21, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug Administration (“FDA”) Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program. Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic...

read more
American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on Tuesday, June 25, 2024

American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on Tuesday, June 25, 2024

Meeting Will be Held at The Hilton Hotel, San Francisco, CA SAN FRANCISCO, CA, May 21, 2024—American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that its Annual Meeting of Shareholders will be held on Tuesday, June 25, 2024, at 9:00 a.m. PT. The Annual Meeting will be an in-person meeting. For those who wish to attend, the...

read more
ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Conference Call on Wednesday, May 15, 2024, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, CA, May 15, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc. On track to ship research use only (RUO) GraftAssureTM transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024.  IVD...

read more
American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on Tuesday, June 25, 2024

American Shared Hospital Services Reports First Quarter 2024 Financial Results

- Reports Record Backlog of $210 million more than doubling following the acquisition of Rhode Island Radiation Therapy Cancer Centers in May 2024 - - Remains on track with opening new Puebla, Mexico center - -Conference Call Today, May 14th at 4:30 pm ET - SAN FRANCISCO, CA, May 14, 2024—American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems...

read more
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

Company Achieves Record-Breaking First Quarter Results for 2024, Marking the Launch of BioStem 2.0 Company Reports First Quarter EBITDA of $4.9 Million Project Continued Growth from Sales of AmnioWrap2 ® Financial Results Conference Call and Webcast on Tuesday, May 14, 2024, at 4:30 pm EDT POMPANO BEACH, FLORIDA, May 14, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived...

read more
ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Oncocyte to Announce First Quarter 2024 Financial Results

Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, CA, May 13, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. Interested parties...

read more
American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on Tuesday, June 25, 2024

American Shared Hospital Services Announces Closing of Acquisition of 60% Majority Interest in Three Radiation Therapy Cancer Centers in Rhode Island

- Adds $9-$10 million in Annual Revenue with Positive Net Income Contribution - - Acquisition more than Doubles Backlog to over $210 million - - Expands U.S. Footprint and Product Offering - SAN FRANCISCO, CA, May 9, 2024—American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced the closing of its acquisition of a...

read more
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Conference Call on Tuesday, May 14th, at 4:30 pm ET POMPANO BEACH, FLORIDA, May 7, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading biotechnology company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, announced today that it plans to release its first quarter 2024 financial results post-market on Tuesday, May 14, 2024. BioStem will host a conference call and webcast at 4:30 pm ET on Tuesday, May 14, 2024. The call...

read more
American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on Tuesday, June 25, 2024

American Shared Hospital Services Announces First Quarter 2024 Earnings Conference Call

SAN FRANCISCO, CA, May 7, 2024—American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a conference call to discuss its first quarter 2024 financial results on Tuesday, May 14th at 4:30 pm ET / 1:30 pm PT. The first quarter 2024 financial results press release will be issued at the market close on...

read more
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Granted Prioritized Examination for Wound Healing Patent

POMPANO BEACH, FLORIDA, May 6, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company’s request for Prioritized Examination for its application for U.S. Patent 18/290,914 titled STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF. “As we...

read more
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts

POMPANO BEACH, FLORIDA, April 30, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived tissue allografts for advanced wound care, today announced that it has retained the services of Mr. Nick McCoy, who will lead BioStem’s Diabetic Foot Ulcer (DFU) and Venous Leg Ulcer (VLU) clinical trials process as a consultant to the Company. BioStem’s clinical focus on completing these...

read more
SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

Company’s flagship SSi Mantra surgical device has now been used in more than 1000 procedures FORT LAUDERDALE, FL, April 29, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the successful performance of the first pyeloplasty procedure performed on an infant utilizing its flagship SSi Mantra...

read more
PRISM MarketView – Weekly Market Report – April 26, 2024 

PRISM MarketView – Weekly Market Report – April 26, 2024 

PRISM Market Pulse: Equities Rally Amid Mixed Big Tech Earnings; Economic Shifts and Sector-Specific Highlights New York, N.Y., April 26, 2024 - PRISM MarketView - Equities were higher through the morning into midday trading as the S&P 500 and Nasdaq are set to snap their three- and four-week losing streaks. Big tech was the topic of Street-talk this week as some of the Magnificent Seven reported earnings. The reports produced mixed and opposite reactions by the Street as Tesla (TSLA)...

read more
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies to Present at the 2024 Planet MicroCap Showcase

BioStem CEO, Jason Matuszewski, will present on Wednesday, May 1, 2024, at 11.30 am PST POMPANO BEACH, FLORIDA, April 25, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 held at the Paris Hotel & Casino, in Las Vegas, NV., from April 30 - May 2 2024....

read more
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior Exchange

Strategic Audit Completion Set to Enhance BioStem Technologies' Market Position and Shareholder Value POMPANO BEACH, FLORIDA, April 24, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today announced the successful completion of comprehensive audits for fiscal years 2022 and 2023. This completion is a significant step in the company’s strategy to uplist to a...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850